1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Marksans Pharma Limited

Marksans Pharma Limited

294.45
INR
-3.70
(-1.24%)
11.51EPS
23.91P/E
123.63BMarket Cap
Nov 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
16.31
19.46
21.58
18.54
22.09
24.12
27.59
33.43
36.16
44.53
47.98
57.69
64.91
70.04
Basic EPS, GAAP
1.87
2.67
1.92
0.22
0.87
1.97
2.95
5.83
4.51
6.41
6.92
8.4
9.22
11.41
Free Cash Flow per Basic Share
1.55
2.88
-2.47
-0.33
1.22
0.67
4.24
3.23
1.29
4.42
0.48
0.74
7.23
- -
Dividend per Share
0.27
0.17
0.44
0.42
0.06
0.11
0.72
0.1
0.26
0.24
0.5
0.6
0.8
- -
Book Value per Share
3.34
8.97
10.87
10.32
11.5
13.25
15.54
21.66
29.37
39.07
45.57
54.44
66.71
- -
Tangible Book Value per Share
1.44
7.42
8.29
7.82
9.23
11.5
13.76
20.02
27.21
36.62
43.27
51.93
63.14
- -
Basic Weighted Avg Shares
385
409
409
409
409
409
409
409
409
415
453
453
453
453
Sales/Revenue/Turnover
6,285
7,967
8,833
7,588
9,041
9,873
11,293
13,684
14,801
18,496
21,742
26,144
29,416
31,717
Operating Margin (%)
15.64
20.06
11.81
0.37
5.71
11.07
14.67
23.29
14.64
16.92
17.82
17.43
17.52
19.34
Depreciation Expense
157
161
281
301
268
228
267
362
448
519
743
834
986
1,004
Net Income, GAAP
719
1,094
785
88
358
804
1,208
2,385
1,846
2,663
3,137
3,806
4,179
5,167
Effective Tax Rate (%)
14.8
28.18
22.56
23.92
28.11
22.88
23.17
21.06
24.52
21.42
25.65
24.08
25.06
24.51
Profit Margin (%)
11.44
13.73
8.89
1.16
3.96
8.15
10.69
17.43
12.47
14.4
14.43
14.56
14.21
16.29
Working Capital
238
2,226
1,891
1,878
2,159
2,988
3,648
6,039
8,450
13,343
14,726
17,268
21,957
- -
LT Debt
198
- -
- -
- -
- -
- -
75
93
414
657
1,900
2,633
2,701
- -
Total Equity
1,488
3,879
4,532
4,397
4,804
5,527
6,491
9,054
12,230
17,651
20,859
24,894
30,527
- -
Return on Invested Capital (%)
25.13
25.43
15.41
2.12
6.34
13.25
18.89
28.44
13.67
14.2
13.3
13.11
11.9
- -
Return on Capital (%)
26.98
25.68
15.06
1.72
6.55
13.59
18.71
29.82
16.4
16.87
15.21
15.07
13.98
- -
Return on Common Equity (%)
66.84
44.12
19.33
2.04
8.02
15.88
20.49
31.33
17.67
18.07
16.47
16.8
15.22
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
732
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2,701
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
453
453
453
Market Capitalization
81,701
71,097
123,628

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
27,227
- -
Cash, Cash Equivalents & STI
- -
9,893
- -
Accounts Receivable, Net
- -
6,446
- -
Inventories
- -
9,723
- -
Total Current Liabilities
- -
5,271
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
732
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.78%
27.91%
22.63%
Free Cash Flow
93.78%
205.25%
870.8%
Net Income, GAAP
55.93%
14.12%
9.81%
Sales/Revenue/Turnover
13.33%
16.69%
12.52%
Total Cash Common Dividend
79.83%
66.15%
33.33%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,906
6,419
6,818
7,085
26,144
2026
6,200
7,204
7,544
8,561
29,416
2027
8,408
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.96
2.13
2.31
2
8.4
2026
1.29
2.17
2.5
3.27
9.22
2027
3.47
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
0.8
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mark Bosco Saldanha
Full Time Employees
1,685
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Grandeur Mumbai MA India 400053
IPO Date
Apr 3, 2002
Website
marksanspharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Marksans Pharma Limited Marksans Pharma Limited engages in the research, manufacturing, marketing, and sale of generic pharmaceutical formulations, with a primary focus on over-the-counter (OTC) and prescription (Rx) products across therapeutic areas including pain management, cough and cold, gastrointestinal, cardiovascular, central nervous system, anti-diabetic, analgesics, upper respiratory, dermatology, anti-allergy, anti-fungal, and vitamins; its product portfolio encompasses plain, enteric-coated, and film-coated tablets, hard and soft gelatin capsules, oral liquids, ointments, creams, and sachets, supported by four state-of-the-art manufacturing facilities in India (Goa units with total capacity exceeding 26 billion units annually), the United Kingdom (Southport), and the United States (Farmingdale), along with four R&D centers. The company, founded in 1992 and headquartered in Mumbai, India, operates in over 50 countries, with key markets in the US (via Time-Cap Labs), UK and Europe (via Marksans Pharma UK Ltd., including Bell Sons & Co. for OTC and Relonchem for Rx), Australia and New Zealand (via Nova Pharmaceuticals), and rest-of-world regions spanning CIS and MENA, supplying leading retailers such as Walmart, Target, Walgreens, and Kroger. Recent developments include the 2023 acquisition of a Teva Pharma manufacturing facility in Goa to expand capacity to 8 billion units annually in phases (with Phase 2 completion targeted by end-FY25), the 2022 acquisition of Access Healthcare in Dubai to bolster Middle East and Africa presence, multiple USFDA and UK MHRA approvals (such as Omeprazole Delayed-Release Tablets and Loratadine Tablets in 2024-2025), over 100 products in pipeline across markets, and a strategic shift toward backward integration for API captive consumption alongside calibrated inorganic growth in Europe.